Navigation Links
Verified Clinical Trials Will Exhibit at the Annual 2013 SCOPE Summit to Discuss the Professional Research Subject and the Clinical Trial Database Registry
Date:1/8/2013

ousands of smaller sites involved in later phase trials as well.

Mitchell Efros MD FACS, the President and CEO of VCT, stated, "We are overwhelmed by the growth Verified Clinical Trials has achieved as well as the recognition by the clinical trial and pharmaceutical industry. We attribute this to the fantastic system we created as well the industry's unwillingness to accept less than perfect data and any potential safety risks to the volunteer."

Kerri Weingard ANP COO added, "We continue to attract and partner with the world's largest and most prominent pharmaceutical and clinical research companies. Our growth has been truly remarkable. This is a direct result of how well our system functions as well as the excellent customer service that VCT provides."

About Verified Clinical Trials
Verified Clinical Trials was developed by experts in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials halts dual enrollment in clinical trials and defines itself as the world's leader in the field of clinical trial database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry that is fully web based and designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally and globally. Verified Clinical Trials is a HIPAA- and 21 CFR part 11- compliant online subject registry to anonymously and securely validate subjects and prevent dual enrollment in multiple concurrent research studies. Verified Clinical Trials offers numerous other value-added services to the clinical research site, CRO, and pharmaceutical sponsor, that prove invaluable with regards to financial and legal issues and liabilities. To RSVP or for more info
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
2. Research Volunteer Registry from Verified Clinical Trials Adopted by ICON
3. WCCT Global (WCCT) & Verified Clinical Trials (VCT) Announce Medication Adherence Documentation Capabilities Have Been Added to the VCT Clinical Trials Database Registry
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Positive Clinical Study Results for BSPs HyperQ Technology
6. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
9. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
10. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company’s latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
(Date:11/18/2014)... November 18, 2014 Alanda Software, ... Transparency Reporting solutions, announced today that a top ... its Consummate Provider™ solution in both the U.S. ... Global, SaaS based, Data Quality remediation portal, designed ... third party Providers improve their ability to capture, ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Inc. (Nasdaq: EXEL ) today announced that ... Inc. (Hudson, NY) pursuant to which Exelixis,sold Taconic ... GmbH,for approximately $20 million, subject to certain post-closing ... and commercialization of,genetically engineered mouse models and engineered ...
... LAKE, N.J., Nov. 20 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... 10mg, 15mg & 20mg. Focalin XR is manufactured ... Holdings Inc. Barr filed its Abbreviated New ...
... FRANKLIN, Mass., Nov. 20 Echo Therapeutics,Inc. (OTC ... quarter ended September 30, 2007. For the quarter ended ... share, compared to $1,390,000 or,$.49 per share, for the ... 30, 2007, net loss was $10,278,000, or $1.05 per ...
Cached Biology Technology:Exelixis Sells 80% Stake in Artemis to Taconic 2Exelixis Sells 80% Stake in Artemis to Taconic 3Exelixis Sells 80% Stake in Artemis to Taconic 4Barr Confirms Patent Challenge of Focalin(R) XR 2Barr Confirms Patent Challenge of Focalin(R) XR 3Echo Therapeutics Reports Third Quarter 2007 Results 2Echo Therapeutics Reports Third Quarter 2007 Results 3Echo Therapeutics Reports Third Quarter 2007 Results 4Echo Therapeutics Reports Third Quarter 2007 Results 5Echo Therapeutics Reports Third Quarter 2007 Results 6
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... was fascinating to put a flashlight up to our ... Washington University in St. Louis engineers are using a ... to improve imaging of cancerous tissues and to develop ... K. Beare Distinguished Professor of Biomedical Engineering at the ... novel time-reversal technology that allows researchers to better focus ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Louis, MO, May 11, 2009 As the childhood obesity ... early parent and child behaviors contribute to the problem. A ... in the May/June 2009 issue of the Journal of ... signs of satiety in their infants tend to overfeed them, ...
... world,s second largest fish hide out for half ... on May 7th in Current Biology , a ... the iconic species and highlights just how little we ... the researchers said. "While commonly sighted in surface ...
... team of researchers from the United States, the Netherlands ... that are associated with altered kidney disease risk. One ... protein, the most common protein in the urine of ... for almost 60 years, its functions are not well ...
Cached Biology News:Does mom know when enough is enough? 2Disappearing act of world's second largest fish explained 2Study finds novel genetic risk factors for kidney disease 2
... HistoMark Biotin Streptavidin-HRP Systems provide ... and intracellular antigens in frozen or ... These systems also facilitate double ... can be performed simultaneously with primary ...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... three step procedure (PCR, Exonuclease III digestion ... one day. The typical cloning efficiency using ... Features and Benefits: , , Universal - ... expression vector , High Cloning Efficiency - ...
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
Biology Products: